Primus In News
Blockbuster semaglutide set to go off patent, Indian pharma sees a multi-billion-dollar opportunity
11-08-2025
Vivek Tandon, Vice President, Primus Partners, shares his view on the opportunities for Indian pharma companies in the semaglutide market. He highlights that India, being the world’s largest supplier of generics with over 20 percent share, is well positioned to disrupt the global market with high-quality semaglutide generics once the drug goes off patent. He added that Indian pharmaceutical majors have been preparing for this opportunity for several years.
Explore Related Insights
- Google to allow limited fantasy sports, rummy games on PlayStore under pilot project
- Indian online gaming industry with considerable growth potential, regulatory changes cause concerns: Report
- Bain-backed Japanese firm Proterial looks to India for rare earth magnet manufacturing
- Tweak LTCG structure if cutting rates not an option, say experts